Navigation Links
Agendia Introduces the SYMPHONY™ Breast Cancer Profile With Paraffin Embedded Tissue
Date:12/6/2011

IRVINE, Calif. and AMSTERDAM, Dec. 6, 2011 /PRNewswire/ -- Agendia, an innovative molecular diagnostics company, today announced the introduction of formalin fixed, paraffin embedded tissue technology applied to their Symphony™ suite of breast cancer assays. Delivering Agendia's tests in a paraffin embedded tissue format offers their customers added convenience along with the superior science, development and validation found in Agendia's breast cancer Symphony suite.

"Agendia's Symphony suite provides physicians with clear insight, helping them to choose a treatment protocol customized for each patient's individual needs," said Agendia's CEO, David Macdonald. "The use of paraffin embedded tissue with these tests will further assist physicians in delivering personalized treatment options."

Agendia's breast cancer Symphony suite of products leverage the predictive and prognostic power of four separate and distinct assays to provide a comprehensive decision support system.  Symphony assists physicians in determining which patients will benefit from chemo therapy, hormonal therapy, or combination therapies, preventing unnecessary suffering from short and long term side effects and burdensome costs to the overall health care system. Symphony includes MammaPrint®, which determines the risk of recurrence;  BluePrint™ determines molecular subtypes; TargetPrint® determines ER, PR and HER2 status; and TheraPrint® identifies alternative types of therapy for metastatic disease.

MammaPrint was the first in vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire clearance from the US Food and Drug Administration (FDA).  Originally offered for fresh tissue specimens, MammaPrint accurately identifies the risk of disease recurrence for patients with early stage breast cancer.

About Agendia:

Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, BluePrint­­, a molecular subtyping assay, TargetPrint, an ER/PR/HER2 expression assay, and TheraPrint, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of breast cancer tests, Agendia has a rich pipeline of genomic products in development based on its world-class quantitative gene expression platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2, MINDACT as well as other trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit www.agendia.com.

For further information, please contact:


Ricochet Public Relations
Todd Aydelotte
Tel: +1 212 679 3300 ext. 111
E-mail: todd@ricochetpr.com


'/>"/>
SOURCE Agendia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Appoints New CEO and Supervisory Board Member
2. Agendia Receives €1.27 Million in Funding from the EUs Seventh Framework Programme
3. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
4. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
5. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
6. FDA Broadens Clearance for Agendias MammaPrint(R)
7. /C O R R E C T I O N -- Agendia B.V./
8. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
9. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
10. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
11. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... and FAIRFIELD, N.J. , ... and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that they ... development and commercialization rights for OPA-15406 in the U.S. ... also provides manufacturing rights.  OPA-15406 is a topical, non-steroidal ... atopic dermatitis. --> --> ...
(Date:2/8/2016)... -- --> --> ... Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) ... Gynecology) - Global Forecasts to 2020", published by MarketsandMarkets, ... period of 2015 to 2020. The market is expected ... 10.5% from 2015 to 2020. Browse 73 ...
(Date:2/8/2016)... , Feb. 8, 2016 In a historic vote among its ... to construct a medical cannabis cultivation facility and dispensary on tribal land ... New York as a provider for patients in the state,s ... as a provider for patients in the state,s Medical Cannabis ... (34) to approve the project and pursue designation from the ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering ... pouches, bags, and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, ... step up to semi-automatic or fully-automatic case packing with a small footprint, rugged, ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, a ... latest beneficiary of their ongoing community enrichment program. The current campaign fundraises for ... Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves ...
(Date:2/8/2016)... ... , ... Remember the old saying “rub some dirt on it”? Perhaps you ... “Calcium Bentonite Clay” the health benefits of integrating clay into a daily diet are ... A former motivational speaker, Perry A~ has since dedicated her life to learning about ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... ... showing greater than 50% lower incidence rate of type 2 diabetes in the ... averages. ”It is time to make a change in public health,” states Carole ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi ... and 11th, 2016 in honor of his birthday on February 10th. During this ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries as ...
Breaking Medicine News(10 mins):